Proud that #DART continues to hit the target! Looking forward to even more!! @PatelOncology @youngkwangchae @Dr_R_Kurzrock @SWOG @theNCI

New #JITC article: Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38) https://t.co/ZejZJvFDyJ

https://t.co/rZcXqjIs4z

Ready to shape the future of cancer care? 🩺 Our new MAS in Precision Medicine Therapeutics in Oncology will equip you with the skills to deliver personalized oncology treatment and drive innovation in precision medicine. Learn more & apply today: https://t.co/862sqJg514

“Emergency powers” again? This time, the President is claiming authority to slap tariffs on Americans under IEEPA, a law that never even mentions tariffs. In this episode of Ask The Judge, Justice Daniel Kelly explains why taxing Americans isn’t just bad policy, it’s

A special congratulations to our Moores Cancer Center physicians named in the 2025 San Diego Magazine “Physicians of Exceptional Excellence” list. Recognized for their leadership, compassion, and impact in cancer care. 👏 See the full list here: https://t.co/GP86Z126hw

In a recent interview with CURE Today, Moores member Dr. Sandip P. Patel says ~10–20% of early-stage NSCLC patients still miss full biomarker testing. "You can’t target what you don’t test." Let’s close the gap between trials & real-world care. Watch:

Watch now to get expert insights on how to interpret the latest evidence supporting the use of different immunotherapy options and combinations in advanced #NSCLC with @JulieBrahmer @PatelOncology. 🔗 https://t.co/DMG5PGD2Mz #Oncology #MedEd #PeerView

The enthusiasm around #AI in medicine comes with questions about the ethical and equitable integration of these tools into clinical practice. For #ASCODailyNews, @PatelOncology and @TaliAzen assess the role of machine learning in oncology today: https://t.co/tMxwpK6GHI

Tune in to watch @lungoncdoc and @PatelOncology, discuss treatment and sequencing considerations in advanced #NSCLC Watch their full discussion here!

New @AmericanCancer report provides statistics on lobular breast cancer. Know the numbers: 🩺~11% of US breast cancers are invasive lobular carcinoma 📈 Incidence rising faster than other breast cancers 📊~33,600 diagnoses expected in 2025 https://t.co/TaWwnPO8qM @OncoAlert

#DCLung25 Kicking off the immunotherapy session @PatelOncology outlines his approach & beyond in 1L NSCLC. Variations in practice include: - subgrps for CTLA4 (KEAP1/STK11, PDL1neg, squam, brain Mets) - ?role of TTF - ?role for Ivonescimab (approved in🇪🇺) @IASLC #LCSM

T-1 day until #DCLung25! 58 faculty will take us on a 1-day journey through all things lung cancer, led by @StephenVLiu & @Joshua_Reuss Great to be in DC representing 🇪🇺🇮🇪 & Happy bday to #TinaCascone Join us! @IASLC @Georgetown @CancerCentreIre #LCSM

Quick pre #DCLung25 visit to the National Portrait Gallery @smithsoniannpg - my favorite museum in DC - with some of the faculty!

Dr. @PatelOncology with a rapid 🔥 breakdown all things IO and novel devices (Tumor treating fields) in the mgmt of advanced NSCLC at #DCLung25.

Dr. @PatelOncology at #DCLung25 shows the impact of immunotherapy in NSCLC as first-line therapy - with long term survival clearly established for a subset of patients. Working on selection for CTLA4 inhibition (STK11, PDL1 0%, squamous, CNS). TTFields data intriguing as well.

Thanks ⁦@ASCO ⁦#ASCODailyNews for sharing our work on “What Is the Role of Machine Learning in Oncology Today?” led by ⁦@UCSDCancer⁩ fellow ⁦@TaliAzen⁩

“The number of assessments for clinical trials has exploded... AI approaches can help reduce friction on the reproducible pain points.” @PatelOncology discusses the potential role of AI in clinical research in the latest CancerSpeak episode: https://t.co/UcgdctXmmD @OncoAlert

Great talk by @Sonampuri @MoffittNews at @SWOG, highlighting the “meandering” path @theNCI cooperative groups can often take as they evolve. I recall the same as @PrimoLaraMD & I were designing #PAPMET. The lesson learned: stick with it! #SWOGonc studies take time but represent

Superb talk by @PatelOncology at the @SWOG Plenary Session, highlighting work from @LeciaSequist, @DrJNaidoo, @FaltasLab (based on #S1314 from @TomFlaigMD @djmcconkey) & others. I was particularly blown away by data I had not seen from @marinagarassino for #TROP2 assessment in

At the @SWOG Plenary Session: amazing talk from @drgandara highlighting the explosion of new therapies/approaches for #lungcancer. @SWOG leading the way w trials showcased from @riess_md, @Annechiangmd, @ReckampK, @JhanelleGray & so many others.